Y Liu1, D Ma1, F Lv1, X Xu1, J Wang5,6, W Xia1, Y Jiang1, O Wang1, X Xing1, W Yu2, J Wang5,6, J Sun3,4, L Song3,4, Y Zhu3,4, H Yang5,6, J Wang5,6, M Li7. 1. Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China. 2. Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China. 3. Tianjin Medical Laboratory, BGI-Tianjin, BGI-Shenzhen, Tianjin, 300308, China. 4. Binhai Genomics Institute, BGI-Tianjin, Tianjin, 300308, China. 5. BGI-Shenzhen, Shenzhen, 518083, China. 6. James D. Watson Institute of Genome Sciences, Hangzhou, 310058, China. 7. Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, 100730, China. limeilzh@sina.com.
Abstract
The achievement of more accurate diagnosis would greatly benefit the management of patients with osteogenesis imperfecta (OI). In this study, we present the largest OI sample in China as screened by next generation sequencing. In particular, we successfully identified 81 variants, which included 45 novel variants. We further did a genotype-phenotype analysis, which helps make a better understanding of OI. INTRODUCTION: This study aims to reveal the gene mutation spectrum and the genotype-phenotype relationship among Chinese OI patients by next generation sequencing (NGS). METHODS: We developed a NGS-based panel for targeted sequencing of all exons of 14 genes related to OI, and performed diagnostic gene sequencing for a cohort of 103 Chinese OI patients from 101 unrelated families. Mutations identified by NGS were further confirmed by Sanger sequencing and co-segregation analysis. RESULTS: Of the 103 patients from 101 unrelated OI families, we identified 79 mutations, including 43 novel mutations (11 frameshift, 17 missense, 5 nonsense, 9 splice site, and 1 chromosome translocation) in 90 patients (87.4%). Mutations in genes encoding type I collagen, COL1A1 (n = 37), and COL1A2 (n = 29) accounts for 73.3% of all molecularly diagnosed patients, followed by IFITM5 (n = 9, 10%), SERPINF1 (n = 4, 4.4%), WNT1 (n = 4, 4.4%), FKBP10 (n = 3, 3.3%), TMEM38B (n = 3, 3.3%), and PLOD2 (n = 1, 1.1%). This corresponds to 75 autosomal dominant inherited (AD) OI patients and 15 autosomal recessive (AR) inherited patients. Compared with AD inherited OI patients, AR inherited patients had lower bone mineral density (BMD) at spine (P = 0.05) and less frequent blue sclera (P = 0.001). Patients with type I collagen qualitative defects had lower femoral neck BMD Z-score (P = 0.034) and were shorter compared with patients with type I collagen quantitative defects (P = 0.022). CONCLUSION: We revealed the gene mutation spectrum in Chinese OI patients, and novel mutations identified here expanded the mutation catalog and genotype and phenotype relationships among OI patients.
The achievement of more accurate diagnosis would greatly benefit the management of patients with osteogenesis imperfecta (OI). In this study, we present the largest OI sample in China as screened by next generation sequencing. In particular, we successfully identified 81 variants, which included 45 novel variants. We further did a genotype-phenotype analysis, which helps make a better understanding of OI. INTRODUCTION: This study aims to reveal the gene mutation spectrum and the genotype-phenotype relationship among Chinese OI patients by next generation sequencing (NGS). METHODS: We developed a NGS-based panel for targeted sequencing of all exons of 14 genes related to OI, and performed diagnostic gene sequencing for a cohort of 103 Chinese OI patients from 101 unrelated families. Mutations identified by NGS were further confirmed by Sanger sequencing and co-segregation analysis. RESULTS: Of the 103 patients from 101 unrelated OI families, we identified 79 mutations, including 43 novel mutations (11 frameshift, 17 missense, 5 nonsense, 9 splice site, and 1 chromosome translocation) in 90 patients (87.4%). Mutations in genes encoding type I collagen, COL1A1 (n = 37), and COL1A2 (n = 29) accounts for 73.3% of all molecularly diagnosed patients, followed by IFITM5 (n = 9, 10%), SERPINF1 (n = 4, 4.4%), WNT1 (n = 4, 4.4%), FKBP10 (n = 3, 3.3%), TMEM38B (n = 3, 3.3%), and PLOD2 (n = 1, 1.1%). This corresponds to 75 autosomal dominant inherited (AD) OIpatients and 15 autosomal recessive (AR) inherited patients. Compared with AD inherited OIpatients, AR inherited patients had lower bone mineral density (BMD) at spine (P = 0.05) and less frequent blue sclera (P = 0.001). Patients with type I collagen qualitative defects had lower femoral neck BMD Z-score (P = 0.034) and were shorter compared with patients with type I collagen quantitative defects (P = 0.022). CONCLUSION: We revealed the gene mutation spectrum in Chinese OI patients, and novel mutations identified here expanded the mutation catalog and genotype and phenotype relationships among OI patients.
Entities:
Keywords:
Genotype-phenotype correlation; Next generation sequencing; Osteogenesis imperfecta
Authors: Mary D Ruppe; Patrick G Brosnan; Kit Sing Au; Phong X Tran; Barbara W Dominguez; Hope Northrup Journal: Clin Endocrinol (Oxf) Date: 2011-03 Impact factor: 3.478
Authors: Fleur S van Dijk; M Carola Zillikens; Dimitra Micha; Markus Riessland; Carlo L M Marcelis; Christine E de Die-Smulders; Janine Milbradt; Anton A Franken; Arjan J Harsevoort; Klaske D Lichtenbelt; Hans E Pruijs; M Estela Rubio-Gozalbo; Rolf Zwertbroek; Youssef Moutaouakil; Jaqueline Egthuijsen; Matthias Hammerschmidt; Renate Bijman; Cor M Semeins; Astrid D Bakker; Vincent Everts; Jenneke Klein-Nulend; Natalia Campos-Obando; Albert Hofman; Gerard J te Meerman; Annemieke J M H Verkerk; André G Uitterlinden; Alessandra Maugeri; Erik A Sistermans; Quinten Waisfisz; Hanne Meijers-Heijboer; Brunhilde Wirth; Marleen E H Simon; Gerard Pals Journal: N Engl J Med Date: 2013-10-02 Impact factor: 91.245
Authors: Peiran Zhou; Yi Liu; Fang Lv; Min Nie; Yan Jiang; Ou Wang; Weibo Xia; Xiaoping Xing; Mei Li Journal: PLoS One Date: 2014-09-19 Impact factor: 3.240
Authors: Haiqing Xu; Zhiwei Zhao; Hong Wang; Ming Ding; Aiqin Zhou; Xiaoyan Wang; Ping Zhang; Christopher Duggan; Frank B Hu Journal: PLoS One Date: 2013-12-06 Impact factor: 3.240
Authors: Steven Mumm; Gary S Gottesman; Deborah Wenkert; Philippe M Campeau; Angela Nenninger; Margaret Huskey; Vinieth N Bijanki; Deborah J Veis; Aileen M Barnes; Joan C Marini; Marina Stolina; Fan Zhang; William H McAlister; Michael P Whyte Journal: Bone Date: 2019-08-28 Impact factor: 4.398
Authors: Sanne Treurniet; Pia Burger; Ebba A E Ghyczy; Frank D Verbraak; Katie R Curro-Tafili; Dimitra Micha; Nathalie Bravenboer; Stuart H Ralston; Ralph de Vries; Annette C Moll; Elisabeth Marelise W Eekhoff Journal: Acta Ophthalmol Date: 2021-05-19 Impact factor: 3.988